

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT

TaurusTrio™ TAVR SYSTEM SUCCESSFULLY COMPLETED THE FIRST COMPASSIONATE USE TREATMENT IN HONG KONG

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that recently, the TaurusTrio™ transcatheter aortic valve replacement (“**TAVR**”) system, indicated for symptomatic, severe aortic regurgitation (“**AR**”), has successfully completed the first compassionate use treatment in Hong Kong.

In January 2024, the Company completed the patient enrollment of the multi-center registration clinical trial of TaurusTrio™ TAVR system in China. The subsequent phase of follow-up assessments is currently in progress. The Company expects to commercialize this product, upon receipt of regulatory approval in China, to address the unmet needs of the extensive patient population suffering from AR.

THE COMPANY MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET TaurusTrio™ TAVR SYSTEM SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, November 18, 2024

As of the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Mr. Jifeng GUAN, Mr. Fei CHEN, Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. Wai Ming YIP and Mr. Huacheng WEI as independent non-executive Directors.